Quick Answer
Rein Therapeutics, Inc. reported Research And Development Expense of $11.03 million for the year ending 2025.
- Rein Therapeutics, Inc. showed a decrease of -22.6% in Research And Development Expense from 2024 to 2025.
- This data is from Rein Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), Rein Therapeutics, Inc.'s Research And Development Expense has grown by 40.8%.
- Historical annual values: Fiscal year 2025: $11.03 million | Fiscal year 2024: $14.25 million | Fiscal year 2023: $3.99 million | Fiscal year 2022: $17.97 million | Fiscal year 2021: $17.01 million | Fiscal year 2020: $11.17 million | Fiscal year 2019: $17.66 million | Fiscal year 2018: $18.45 million | Fiscal year 2017: $14.24 million | Fiscal year 2016: $10.28 million | Fiscal year 2015: $7.83 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: